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health care costs per controlled patient. Sensitivity analysis
showed that the base study case was robust.
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OBJECTIVE: To compare the economic impact of treating 
neuropathic pain with pregabalin versus gabapentin in Italy.
METHODS: A cost-effectiveness analysis comparing costs and
effects of pregabalin 375 mg/die versus gabapentin 1800 mg/die
in the perspective of the Italian National Health care Service was
developed. The cost effectiveness is examined alternatively in
terms of the incremental cost per additional day with no or mild
pain, and the incremental cost per quality-adjusted life-year
(QALY) gained. Effects were derived from pregabalin random-
ized clinical study 1008-155 and gabapentin 645-210 and 945-
211 studies. Effects are expressed as score reductions on the VAS
pain scale. Pharmacological costs were quantiﬁed according to
the Italian market price of the drugs; health care procedure and
hospitalization costs were quantiﬁed on the basis of the National
Tariff. Other health care services consumption data were derived
from a Delphi Panel. To estimate daily pain experience in
patients with neuropathic pain, and the impact of pregabalin and
gabapentin on it, a stochastic model is used. The dynamic sim-
ulation focuses on a hypothetical cohort of 1000 patients and
simulates their daily pain experience over 12 weeks, to estimate
clinical and economic outcomes for the group as a whole.
RESULTS: The cost-effectiveness ratio for the use of pregabalin
is less than 1 euro per additional day with no or mild pain and
€468 per QALY gained. The sensitivity analysis conducted to
examine the effects of decreasing gabapentin dose to 1200 mg/die
shows consistency of the model results. CONCLUSIONS:
Although pregabalin pharmaceutical costs are higher than
gabapentin costs, the analyses prove pregabalin to be more effec-
tive with a small additional cost per day with no or mild pain.
PND5
TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH
RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COST-
EFFECTIVE TREATMENT STRATEGY IN FINLAND?
Armand C1, Eckert L1,Yrjönen T2
1H. Lundbeck A/S, Paris, France, 2Oy H. Lundbeck Ab,Turku, Finland
OBJECTIVE: Levodopa is the “gold standard” for the sympto-
matic treatment of Parkinson’s Disease (PD) but its beneﬁts
decrease as the disease progresses and motor complications
appear over time. To delay these complications and the need for
levodopa, dopamine agonists (DAs) have been employed as
monotherapy. Our aim was to perform a cost-effectiveness analy-
sis of initiating treatment with rasagiline versus ropinirole in
delaying therapy with levodopa in early PD. METHODS: A 5-
year probabilistic Markov model simulating treatment pathways
of early parkinsonian patients was used to estimate the incre-
mental cost-effectiveness ratio of starting treatment with rasagi-
line or ropinirole. Transition probabilities were derived from
randomized clinical trials and the effectiveness measure was the
number of years until levodopa was required. Since the greatest
portion of direct medical costs of early PD can be attributed to
medication, the model focused on pharmacological treatment
costs and more especially on pharmacy selling prices. In accor-
dance with Finnish health economic guidelines, a 5% discount
rate was applied to both costs and beneﬁts. RESULTS: Begin-
ning treatment of early PD patients with rasagiline delayed time
before levodopa initiation of one year compared with ropinirole
(3.8 vs. 2.8 years). Incremental cost-effectiveness was in favor of
rasagiline with an ICER of €1200 per year gained without lev-
odopa. Initiating treatment with rasagiline has a 95% probabil-
ity of being cost-effective supposing that ropinirole dosage varies
linearily among time. CONCLUSION: This economic model
suggests that initiating treatment with rasagiline for early PD is
more effective in delaying time to levodopa compared with
ropinirole. Further studies are required to link the surrogate end-
point (time without levodopa) to ﬁnal outcomes (QALY, mor-
tality, morbidity).
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OBJECTIVES: There are two preparations of Botulinum toxin
type A—BOTOX and Dysport. Based on BNF prices, the dose
ratio (units of Dysport : BOTOX) for cost equivalence is 4.2 : 1,
however the two products are not interchangeable and there is
no handy conversion factor. This study examined the dose
requirements in a cohort of patients with dystonia who were sta-
bilised ﬁrst on Dysport then on BOTOX. The main objective was
to evaluate the costs of each product in clinical practice.
METHODS: Data was extracted retrospectively from case notes.
Patients were included in the analysis if they had received each
product for at least one year and had demonstrated a response
to both. Those changed back to Dysport at any time during the
2-year period following the switch were excluded. Injections
given in the 1-year period before the switch and between 1 and
2 years after the switch were included in the analysis. The mean
dose of each toxin, the ratio and corresponding costs (from latest
BNF) were calculated. RESULTS: Forty-two patients received
300 administrations. For spasmodic torticollis (36 patients) the
mean doses of BOTOX and Dysport were 89 (range 53 to 120)
and 397 (range 200 to 500) units respectively. The mean ratio
for this indication (Dysport : BOTOX) was found to be 4.48 : 1
(95% conﬁdence interval 4.22 : 1 to 4.73 : 1; range 2.6 : 1 to 
6.3 : 1). For this indication, the mean costs per administration
were found to be ≤115 and ≤122 based on units used and ≤140
and ≤153 based on whole vials for BOTOX and Dysport respec-
tively. Similar ratios were found for other types of dystonia
giving an overall mean dose ratio of 4.56 : 1 (Dysport : BOTOX).
CONCLUSION: This study is consistent with previous work
that has shown that BOTOX is associated with lower costs than
Dysport.
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OBJECTIVE: To explore possible explicative variables of health
and non-health costs related with patient’s life and treatment
